論文

査読有り 国際誌
2017年10月

Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

JOURNAL OF PEDIATRICS
  • Francesca Minoia
  • Francesca Bovis
  • Sergio Davi
  • Antonella Insalaco
  • Kai Lehmberg
  • Susan Shenoi
  • Sheila Weitzman
  • Graciela Espada
  • Yi-Jin Gao
  • Jordi Anton
  • Toshiyuki Kitoh
  • Ozgur Kasapcopur
  • Helga Sanner
  • Rosa Merino
  • Itziar Astigarraga
  • Maria Alessio
  • Michael Jeng
  • Vyacheslav Chasnyk
  • Kim E. Nichols
  • Zeng Huasong
  • Caifeng Li
  • Concetta Micalizzi
  • Nicolino Ruperto
  • Alberto Martini
  • Randy Q. Cron
  • Angelo Ravelli
  • AnnaCarin Horne
  • 全て表示

189
開始ページ
72
終了ページ
+
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.jpeds.2017.06.005
出版者・発行元
MOSBY-ELSEVIER

Objective To develop and validate a diagnostic score that assists in discriminating primary hemophagocytic lymphohistiocytosis (pHLH) from macrophage activation syndrome (MAS) related to systemic juvenile idiopathic arthritis.
Study design The clinical, laboratory, and histopathologic features of 362 patients with MAS and 258 patients with pHLH were collected in a multinational collaborative study. Eighty percent of the population was assessed to develop the score and the remaining 20% constituted the validation sample. Variables that entered the best fitted model of logistic regression were assigned a score, based on their statistical weight. The MAS/HLH (MH) score was made up with the individual scores of selected variables. The cutoff in the MH score that discriminated pHLH from MAS best was calculated by means of receiver operating characteristic curve analysis. Score performance was examined in both developmental and validation samples.
Results Six variables composed the MH score: age at onset, neutrophil count, fibrinogen, splenomegaly, platelet count, and hemoglobin. The MH score ranged from 0 to 123, and its median value was 97 (1st-3rd quartile 75123) and 12 (1st-3rd quartile 11-34) in pHLH and MAS, respectively. The probability of a diagnosis of pHLH ranged from < 1% for a score of < 11 to >99% for a score of >= 123. A cutoff value of >= 60 revealed the best performance in discriminating pHLH from MAS.
Conclusion The MH score is a powerful tool that may aid practitioners to identify patients who are more likely to have pHLH and, thus, could be prioritized for functional and genetic testing.

リンク情報
DOI
https://doi.org/10.1016/j.jpeds.2017.06.005
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28807357
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000417154100019&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.jpeds.2017.06.005
  • ISSN : 0022-3476
  • eISSN : 1097-6833
  • PubMed ID : 28807357
  • Web of Science ID : WOS:000417154100019

エクスポート
BibTeX RIS